/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
Diamyd Medical AB (publ)
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
DMYD | ST
Overview
Corporate Details
- ISIN(s):
- SE0005162872 (+5 more)
- LEI:
- 5493003NP2HNQDEKB804
- Country:
- Sweden
- Address:
- BOX 7349, 103 90 STOCKHOLM
- Website:
- https://www.diamyd.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Diamyd Medical AB is a clinical-stage company developing precision medicine therapies to prevent and treat autoimmune diabetes, primarily Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA). Its lead product candidate, Diamyd®, is an antigen-specific immunotherapy designed to preserve the body's own insulin-producing capabilities. The therapy, administered intralymphatically, targets individuals with a specific HLA genotype. Diamyd® is undergoing evaluation in the pivotal Phase 3 trial, DIAGNODE-3, and the Phase 2 prevention trial, DiaPrecise. The company is also establishing a facility for the manufacturing of its biological active ingredient, GAD65.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Diamyd Medical AB (publ) filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Diamyd Medical AB (publ)
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Diamyd Medical AB (publ) via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
